Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 5/20 | 0.51 |
| ▸ | BCHE | P06276 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RGS4 | P49798 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19147985 | 0.94 | CNR2 (0.63) | CNR2ADRA2AACHEBCHEALDH1A1 | |
| SCHEMBL8175634 | 0.89 | ADRA2A (0.50) | CNR2ADRA2AACHEBCHEALDH1A1 | |
| SCHEMBL4469156 | 0.88 | CNR2 (0.49) | CNR2ADRA2AACHEBCHEALDH1A1 | |
| SCHEMBL8174724 | 0.87 | ALDH1A1 (0.55) | CNR2ADRA2AACHEBCHEALDH1A1 | |
| SCHEMBL11730694 | 0.84 | ADRA2A (0.44) | CNR2ADRA2AACHEBCHEALDH1A1 | |
| SCHEMBL27169532 | 0.80 | CNR2 (0.55) | CNR2ADRA2AACHEBCHEALDH1A1 | |
| SCHEMBL2336285 | 0.79 | ALDH1A1 (0.45) | CNR2ADRA2AALDH1A1RGS4L3MBTL1 | |
| SCHEMBL11556471 | 0.78 | ALDH1A1 (0.52) | CNR2ACHEBCHEALDH1A1POLB | |
| SCHEMBL29022236 | 0.78 | POLB (0.68) | CNR2ADRA2AALDH1A1POLBKDM4E | |
| SCHEMBL13349387 | 0.77 | ALDH1A1 (0.41) | CNR2ADRA2AALDH1A1RGS4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144764-A1 | PYRIMIDINEDIONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | CNR2 21/4885ADRA2A 11/4885ACHE 1383/4885 |
| US-20100144764-A1 | PYRIMIDINEDIONE DERIVATIVES AND METHODS OF USE THEREOF | DPYD, TYMS, FPGS | CNR2 2148/4885ADRA2A 3190/4885ACHE 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.